| Autor: |
Olena Said, Dominic Stringer, Ece Sengun Filiz, Hiba Mutwalli, Sevgi Bektas, Melahat Nur Akkese, Vanessa Kellermann, Katie Ireland, Elizabeth Tyrrell-Bunge, Demelza Beishon-Murley, Joel W. T. Khor, Lee Allman, Joanna Barker, Nicus Kotze, Ben Carter, Mima Simic, Dilveer Singh Sually, Jessica Bentley, Allan H. Young, Sloane Madden, Sarah Byford, Sabine Landau, Vanessa Lawrence, Janet Treasure, Ulrike Schmidt, Dasha Nicholls, Hubertus Himmerich |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
BMC Psychiatry, Vol 24, Iss 1, Pp 1-11 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1471-244X |
| DOI: |
10.1186/s12888-024-06215-y |
| Popis: |
Abstract Background Despite the availability of evidence-based treatments for anorexia nervosa (AN), remission rates are moderate, and mortality is high. Olanzapine is used as adjunct therapy for AN in case of insufficient response to first-line treatments, even though the evidence is limited. Its effect on eating disorder (ED) psychopathology, its efficacy and tolerability, and its acceptability and adherence rate are unclear. Methods We assessed the feasibility of a future definitive trial on olanzapine in young people with AN in an open-label, one-armed feasibility study that aimed to include 55 patients with AN or atypical AN aged 12–24 who gained |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
